Shinkichi Takamori, Yasushi Yatabe, Atsushi Osoegawa, Keiju Aokage, Hiroshige Yoshioka, Tomohiro Miyoshi, Takahiro Mimae, Makoto Endo, Aritoshi Hattori, Masaya Yotsukura, Tetsuya Isaka, Mitsuhiro Isaka, Tomohiro Maniwa, Ryu Nakajima, Shun-Ichi Watanabe
Salivary gland-type tumor (SGT) of the lung, which arises from the bronchial glands of the tracheobronchial tree, was first recognized in the 1950s. SGT represents less than 1% of all lung tumors and is generally reported to have a good prognosis. Mucoepidermoid carcinoma (MEC) and adenoid cystic carcinoma (ACC) are the two most common subtypes, comprising more than 90% of all SGTs. The reported 5-year survival rate of patients with SGT is 63.4%. Because this type of tumor develops in major bronchi, patients with SGT commonly present with symptoms of bronchial obstruction, including dyspnea, shortness of breath, wheezing, and coughing; thus, the tumor is usually identified at an early stage...
November 10, 2023: Japanese Journal of Clinical Oncology